Jolanda Howe - Mirum Pharmaceuticals Senior Controller
| MIRM Stock | USD 43.95 0.94 2.19% |
Executive
Jolanda Howe is Senior Controller of Mirum Pharmaceuticals
| Address | 950 Tower Lane, Foster City, CA, United States, 94404 |
| Phone | (650) 667-4085 |
| Web | https://www.mirumpharma.com |
Latest Insider Transactions
Jolanda Howe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jolanda Howe against Mirum Pharmaceuticals stock is an integral part of due diligence when investing in Mirum Pharmaceuticals. Jolanda Howe insider activity provides valuable insight into whether Mirum Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Mirum Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mirum Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jolanda Howe over a month ago Disposition of 1064 shares by Jolanda Howe of Mirum Pharmaceuticals at 48.2225 subject to Rule 16b-3 | ||
Jolanda Howe over a month ago Disposition of 1772 shares by Jolanda Howe of Mirum Pharmaceuticals subject to Rule 16b-3 |
Mirum Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0831) % which means that it has lost $0.0831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3708) %, meaning that it created substantial loss on money invested by shareholders. Mirum Pharmaceuticals' management efficiency ratios could be used to measure how well Mirum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of March 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.17. At this time, Mirum Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 11th of March 2025, Non Current Assets Total is likely to grow to about 291.9 M, while Non Currrent Assets Other are likely to drop about 5.5 M.Mirum Pharmaceuticals currently holds 317.76 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Mirum Pharmaceuticals has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mirum Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tino Anthamatten | MoonLake Immunotherapeutics | N/A | |
| Brian Piekos | Kalvista Pharmaceuticals | 50 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Sr DO | Larimar Therapeutics | 63 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Bethany Dudek | Arcutis Biotherapeutics | N/A | |
| Kent Taylor | Arcutis Biotherapeutics | N/A | |
| Julian Baker | Blueprint Medicines Corp | 58 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Todd Tucker | Arcutis Biotherapeutics | N/A | |
| Brian JD | Kalvista Pharmaceuticals | 57 | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Michael PharmD | Kalvista Pharmaceuticals | 45 | |
| Melita Jung | Terns Pharmaceuticals | 48 | |
| Emil MD | Terns Pharmaceuticals | 45 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Gopi MBA | Larimar Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.0831 |
Mirum Pharmaceuticals Leadership Team
Elected by the shareholders, the Mirum Pharmaceuticals' board of directors comprises two types of representatives: Mirum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mirum. The board's role is to monitor Mirum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Mirum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mirum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter MBA, Chief Officer | ||
| Ian Clements, Chief Officer | ||
| MSC MBA, Chief Officer | ||
| Christopher Peetz, CEO Director | ||
| Jolanda Howe, Senior Controller | ||
| Eric MBA, Chief Officer | ||
| Paul Ross, Chief Officer | ||
| Joanne MD, Chief Officer | ||
| Pamela Vig, Chief Research | ||
| Erin Campany, Senior Resources | ||
| Vinita Kumar, Senior Quality | ||
| Andrew McKibben, Strategic President | ||
| JeanLuc Girardet, Senior Operations |
Mirum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mirum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.0831 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 2.17 B | ||||
| Shares Outstanding | 49.01 M | ||||
| Shares Owned By Insiders | 2.68 % | ||||
| Shares Owned By Institutions | 97.32 % | ||||
| Number Of Shares Shorted | 6.61 M | ||||
| Price To Earning | (5.20) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.